高级搜索

LSD1调控Foxo3a对卵巢癌细胞增殖和迁移的影响

王品昊, 钱尧, 周昱霖, 魏野, 吴朝阳

王品昊, 钱尧, 周昱霖, 魏野, 吴朝阳. LSD1调控Foxo3a对卵巢癌细胞增殖和迁移的影响[J]. 肿瘤防治研究, 2018, 45(8): 545-549. DOI: 10.3971/j.issn.1000-8578.2018.17.1548
引用本文: 王品昊, 钱尧, 周昱霖, 魏野, 吴朝阳. LSD1调控Foxo3a对卵巢癌细胞增殖和迁移的影响[J]. 肿瘤防治研究, 2018, 45(8): 545-549. DOI: 10.3971/j.issn.1000-8578.2018.17.1548
WANG Pinhao, QIAN Yao, ZHOU Yulin, WEI Ye, WU Chaoyang. Effect of LSD1 on Proliferation and Metastasis of Ovarian Cancer Cells by Regulating Foxo3a[J]. Cancer Research on Prevention and Treatment, 2018, 45(8): 545-549. DOI: 10.3971/j.issn.1000-8578.2018.17.1548
Citation: WANG Pinhao, QIAN Yao, ZHOU Yulin, WEI Ye, WU Chaoyang. Effect of LSD1 on Proliferation and Metastasis of Ovarian Cancer Cells by Regulating Foxo3a[J]. Cancer Research on Prevention and Treatment, 2018, 45(8): 545-549. DOI: 10.3971/j.issn.1000-8578.2018.17.1548

LSD1调控Foxo3a对卵巢癌细胞增殖和迁移的影响

详细信息
    作者简介:

    王品昊(1991-),男,硕士在读,主要从事肿瘤分子生物学的研究

    通讯作者:

    吴朝阳,E-mail:wuchaoyang9@163.com

  • 中图分类号: R737.31

Effect of LSD1 on Proliferation and Metastasis of Ovarian Cancer Cells by Regulating Foxo3a

More Information
  • 摘要:
    目的 

    探讨赖氨酸特异性去甲基化酶1(LSD1)如何通过调控转录因子Foxo3a影响卵巢癌细胞增殖和迁移。

    方法 

    实验组A:取诱导型稳定干扰LSD1表达的人卵巢癌HO8910细胞株(HO8910-LSD1-shRNA)分为观察组和对照组,蛋白质印迹法检测LSD1和Foxo3a蛋白表达水平;实验组B:将HO8910-LSD1-shRNA细胞分为对照组、Dox组、A6730组和联合组,CCK-8检测各组细胞增殖抑制率,Transwell小室检测各组细胞迁移能力,蛋白质印迹法检测EMT相关蛋白表达。

    结果 

    在实验组A中,观察组LSD1蛋白水平随Dox浓度增加逐渐下降,而Foxo3a蛋白表达水平逐渐升高。在实验组B中,与对照组比较,Dox组、A6730组和联合组细胞增殖抑制率、细胞迁移率均显著减少(均P < 0.05);联合组较Dox组,细胞增殖抑制率、细胞迁移率均显著减少(均P < 0.05)。与对照组比较,Dox组、A6730组和联合组E-cadherin蛋白表达水平明显升高,而N-cadherin和Snail蛋白水平降低。与Dox组和A6730组比较,联合组E-cadherin表达量增加,而N-cadherin及Snail表达量减少。

    结论 

    敲低LSD1基因表达可以上调转录因子Foxo3a蛋白水平,从而抑制卵巢癌HO8910细胞增殖和转移。

     

    Abstract:
    Objective 

    To investigate the effects of lysine-specific demethylation 1 (LSD1) on the proliferation and metastasis of ovarian cancer cells by regulating Foxo3a.

    Methods 

    In test group A, the human ovarian cancer cell line HO8910 (HO8910-LSD1-shRNA) with inducible stable knockdown of LSD1 expressions were divided into the observation groups and the control group. The expression levels of LSD1 and Foxo3a proteins were detected by Western blot. Then in test group B, the HO8910-LSD1-shRNA cells were divided into Control group, Dox group, A6730 group and Dox+A6730 group. The cell proliferation inhibition rate of each group was detected by CCK-8, and the metastasis levels of each group were detected by Transwell assay. The EMT-related proteins expressions were detected by Western blot.

    Results 

    In test group A, with the increasing Dox concentration in the observation groups, the expression level of LSD1 protein was gradually decreased, while the expression level of Foxo3a protein was gradually increased. In test group B, compared with the control group, the proliferation inhibition rates, cell migration rates of Dox group, A6730 group and combination group were significantly lower (P < 0.05); cell proliferation inhibition rate and cell migration rate of the Dox+A6730 group were significantly lower than those of Dox group (both P < 0.05). Compared with the control group, the expression levels of E-cadherin protein in Dox group, A6730 group and combination group were increased significantly, while the levels of N-cadherin and Snail protein were decreased. Compared with Dox and A6730 groups, the expression of E-cadherin was increased, while the expression of N-cadherin and Snail were decreased in the combination group.

    Conclusion 

    Knocking down the expression of LSD1 gene could upregulate the transcription factor Foxo3a protein level, thereby inhibiting the proliferation metastasis of ovarian cancer HO8910 cells.

     

  • 目前,乳腺癌严重威胁着女性的健康。在乳腺癌的转移机制中,上皮间质转化(epithelial-mesenchymal transition, EMT)是其中一个核心的生物学进程,与乳腺癌的侵袭和转移密切相关。JMJD3又称赖氨酸去甲基化酶6B(lysine demethylase 6B, KDM6B)作为一种Lys27位点三甲基化组蛋白H3(histone H3 methylated Lys27,H3K27me3)去甲基化酶[1],其异常表达与多种肿瘤的发生、发展密切相关[2-3]。JMJD3在肿瘤中是促癌基因还是抑癌基因研究报道尚不一致,有关JMJD3在乳腺癌中的作用,以及JMJD3与上皮间质转化的相关性尚未见类似报道。本研究收集120例乳腺浸润性导管癌组织标本,采用免疫组织化学法检测JMJD3和上皮间质转化相关蛋白E-cadherin、Vimentin和N-cadherin的表达,并分析其相关性及临床病理意义,以拓展和丰富人们对乳腺癌发病机制的认识。

    收集郑州人民医院2014年1月—2015年12月间收治的120例乳腺原发浸润性导管癌及相应的癌旁病理活检标本和相关临床资料。患者术前均未接受放疗或化疗。按照2012年WHO乳腺癌组织病理分级分类法对其进行分组。所有标本均经10%的甲醛固定,石蜡包埋,并经郑州人民医院病理科确诊。

    JMJD3一抗兔抗人多克隆抗体购自英国Abcam公司,E-cadherin、Vimentin和N-cadherin一抗兔抗人单克隆抗体(即用型)、二抗及二氨基联苯胺(DAB)均为福州迈新公司产品。

    主要步骤如下:(1)石蜡组织切片、烤片、脱蜡并水化;(2)EDTA抗原修复;(3)兔抗人单克隆抗体一抗37℃孵育2 h;(4)二抗37℃孵育20~30 min;(5)DAB显色5~10 min;(6)脱水、透明和封片。用已知JMJD3、E-cadherin、Vimentin和N-cadherin阳性的乳腺癌组织和PBS分别代替一抗作为阳性和空白对照。

    JMJD3阳性信号呈棕褐色,表达于细胞核;E-cadherin和N-cadherin阳性信号为棕黄色,表达于细胞膜;Vimentin阳性信号为棕黄色,表达于细胞质。按样本中JMJD3、E-cadherin、Vimentin及N-cadherin阳性细胞占总细胞的比例分为4个等级[4]: < 5%为阴性、5%~ < 25%为弱阳性、25%~50%为中等阳性、≥50%为强阳性。其中阴性和弱阳性判断为低表达,中等阳性和强阳性判断为高表达,阳性表达率=(中等阳性+强阳性样本量)/总样本量,免疫组织化学的判读由两位高年资病理医师采用双盲法进行。

    采用SPSS17.0统计软件进行数据处理与统计分析,JMJD3、E-cadherin、Vimentin和N-cadherin阳性表达率和病理因素的相关性采用χ2检验,蛋白间的相关性采用Spearman相关分析,以P < 0.05为差异有统计学意义。

    JMJD3主要定位于细胞核,在乳腺浸润性导管癌及癌旁组织中呈棕褐色,在导管癌中的阳性表达率明显低于癌旁组织,差异有统计学意义(χ2=7.326, P=0.007),见图 1表 1。JMJD3表达较高者,组织学分化程度高,细胞黏附性强,极性较好,JMJD3表达较低者,组织学分化程度差,细胞黏附性下降,失去极性,细胞梭形更为明显,见图 2

    图  1  JMJD3、E-cadherin、Vimentin和N-cadherin在乳腺浸润性导管癌及癌旁组织中的表达(IHC ×200)
    Figure  1  Expression of JMJD3, E-cadherin, Vimentin and N-cadherin in breast cancer tissues and adjacent tissues (IHC ×200)
    A: adjacent tissues; B: breast cancer.
    表  1  乳腺癌和癌旁组织中JMJD3、E-cadherin、Vimentin及N-cadherin的阳性表达(n(%))
    Table  1  Expression of JMJD3, E-cadherin, Vimentin and N-cadherin in breast cancer tissues and adjacent tissues (n(%))
    下载: 导出CSV 
    | 显示表格
    图  2  乳腺癌JMJD3表达对细胞形态的影响(HE ×200)
    Figure  2  Effects of JMJD3 expression on morphology of breast cancer cells (HE ×200)
    A: high expression of JMJD3; B: low expression of JMJD3.

    E-cadherin在乳腺浸润性导管癌及癌旁组织中主要定位于细胞膜,为粗细相对均匀的棕褐色颗粒,乳腺浸润性导管癌中E-cadherin阳性表达率明显低于癌旁组织,差异有统计学意义(χ2=10.256, P=0.001)。Vimentin主要表达于上皮周围的间质细胞中,在癌及癌旁组织中主要定位于细胞质,为粗细不等的棕褐色颗粒,乳腺浸润性导管癌中Vimentin阳性表达率明显高于癌旁组织,差异有统计学意义(χ2=24.033, P=0.000)。N-cadherin在癌及癌旁组织中主要定位于细胞膜,为粗细相对均匀的棕褐色颗粒,乳腺浸润性导管癌中N-cadherin阳性表达率为明显高于癌旁组织,差异有统计学意义(χ2=35.281, P=0.000),见图 1表 1

    在乳腺浸润性导管癌中,JMJD3与肿瘤直径(χ2=9.697, P=0.008)、组织学分级(χ2=27.313, P=0.000)、淋巴结转移(χ2=12.587, P=0.000)TNM分期有关(χ2=12.385, P=0.000),与乳腺癌患者年龄和肿瘤位置均无关(均P > 0.05)。E-cadherin在高分化、中分化和低分化乳腺癌中表达率依次降低,差异具有统计学意义(χ2=14.152, P=0.001);其在淋巴结有转移组中低于无淋巴结转移组,差异有统计学意义(χ2=9.903, P=0.002);其在TNM Ⅲ期、Ⅳ期组别低于Ⅰ期、Ⅱ期组别,差异具有统计学意义(χ2=20.771, P=0.000)。E-cadherin与乳腺癌患者年龄、肿瘤位置和肿瘤直径均无关(均P > 0.05)。Vimentin在高分化、中分化和低分化乳腺癌中表达率依次升高,差异具有统计学意义(χ2=28.410, P=0.000);其在淋巴结有转移组中高于无淋巴结转移组(χ2=14.090, P=0.000),TNMⅢ期、Ⅳ期组高于Ⅰ期、Ⅱ期组(χ2=13.218, P=0.000),与年龄、肿瘤位置和肿瘤直径均无关(均P > 0.05)。N-cadherin在高分化、中分化和低分化中表达率依次升高(χ2=28.410, P=0.000);其在淋巴结有转移组中高于无淋巴结转移组(χ2=17.678, P=0.000),在TNM Ⅲ期、Ⅳ期组高于Ⅰ期、Ⅱ期组(χ2=30.035, P=0.000)。N-cadherin与乳腺癌患者年龄、肿瘤位置及肿瘤直径均无关(均P > 0.05),见表 2

    表  2  乳腺癌中JMJD3、E-cadherin、Vimentin及N-cadherin的表达与临床病理特征的关系(n(%))
    Table  2  Correlation of JMJD3, E-cadherin, Vimentin and N-cadherin expression with clinicopathological characteristics of breast cancer patients (n(%))
    下载: 导出CSV 
    | 显示表格

    采用Spearman相关分析,结果显示JMJD3和E-cadherin表达呈正相关(r=0.204, P=0.025)。JMJD3和Vimentin表达呈负相关(r=-0.467, P=0.000)。JMJD3和N-cadherin表达呈负相关(r=-0.500, P=0.000),见表 3

    表  3  乳腺癌中JMJD3与E-cadherin, Vimentin和N-cadherin的Spearman相关性分析
    Table  3  Spearman correlation analysis of JMJD3 expression with E-cadherin, Vimentin and N-cadherin expression in breast cancer tissues
    下载: 导出CSV 
    | 显示表格

    JMJD3编码基因位于人类第17号染色体上,其异常表达与肿瘤的发生发展有密切关系。Tokunaga等[5]对151例结肠癌患者的术后生存分析结果表明,JMJD3低表达者术后生存期普遍较短,且回归分析表明JMJD3的低表达是患者不良预后的独立危险因素之一。国内有研究发现JMJD3过表达对胃癌细胞的增殖具有抑制作用,对细胞凋亡具有促进作用[6]。胡贺芳等[7]研究发现JMJD3表达降低可能促进肺癌的发生发展。李彦伟等[8]发现胶质瘤细胞中JMJD3较瘤旁组织表达降低,其过表达可增强胶质瘤细胞迁移能力,该机制通过影响SNAIL基因调控区H3K27me3水平而调节胶质瘤侵袭过程[9]

    JMJD3是促癌基因还是抑癌基因研究报道尚不一致,本研究采用免疫组织化学方法发现JMJD3在乳腺浸润性导管癌组织表达率较癌旁组织低,其在组织学分化差、有淋巴结转移及较高TNM分期的组织中表达率减低,提示JMJD3在乳腺癌的浸润转移中扮演了抑癌基因的角色。此外本研究结果还显示JMJD3低表达与肿瘤直径相关,肿瘤直径的大小反映细胞增殖能力,我们推测JMJD3对乳腺癌细胞增殖具有抑制作用,这与以往其在胃癌研究报道观点一致[6]

    在乳腺癌的转移机制中,EMT是其中一个核心的生物学进程。EMT的过程中,上皮细胞标志性蛋白E-cadherin减少,而间质细胞标志性蛋白Vimentin和N-cadherin表达量上升[10-12]。E-cadherin主要分布于胚胎组织和成熟组织的上皮细胞中,除具有调节胚胎组织的发育、组织形成、参与细胞与细胞间信息传递交流等作用外,对促进细胞的黏附聚集、维持上皮形态结构完整性、极性和参与分化调节也至关重要。Vimentin主要表达于间叶组织和淋巴造血细胞,在上皮中几乎不表达,当细胞出现上皮间质转化时可有表达。N-cadherin表达于神经外胚层和中胚层来源的组织,正常上皮组织不表达或低表达。N-cadherin在上皮组织中的异位表达可以影响上皮细胞的形态和行为,诱导其向间质转化,即产生EMT。

    本研究结果显示从乳腺癌旁组织到乳腺癌组织JMJD3和E-cadherin阳性率逐渐减少,而Vimentin和N-cadherin阳性率逐渐增高;同时它们均与乳腺癌分化程度、TNM分期和淋巴结转移相关,表明JMJD3和EMT相关蛋白共同参与乳腺癌的发生、发展,其可能机制是通过降低肿瘤细胞间的黏附力,使乳腺癌更容易发生浸润和转移。本研究中E-cadherin、Vimentin和N-cadherin的表达情况与以往文献报道的结果基本一致[13-14]

    通过查阅国内外文献,我们发现JMJD3表达对上皮间质转化的影响在胶质瘤细胞[15]、肝癌细胞[16-17]、肾癌细胞[18]和弥漫大B细胞淋巴瘤[19]已有研究报道,其在乳腺癌中尚未见研究报道。上述研究均表明JMJD3过表达能够促进上皮间质转化过程进而促进肿瘤的浸润转移。本研究相关分析结果发现JMJD3与E-cadherin表达呈正相关,与Vimentin和N-cadherin表达呈负相关,表明JMJD3低表达可能通过下调E-cadherin及上调Vimentin和N-cadherin的表达使乳腺癌上皮细胞获得间质细胞的特性,进而促进EMT的发生。提示JMJD3阳性率较低的乳腺癌患者更易发生淋巴结转移和较差的组织学分化,而组织学分化较差的乳腺癌细胞在形态学上细胞极性消失,细胞梭形明显,黏附性下降,从形态学上表明JMJD3可能通过上皮间质转化途径参与乳腺癌的发生发展。本研究从蛋白水平对乳腺癌中JMJD3、E-cadherin和Vimentin表达进行分析,尚缺少分子生物学调节实验,还需进一步深入研究。

    综上所述,乳腺浸润性导管癌中组蛋白去甲基化酶JMJD3与E-cadherin呈正相关,与Vimentin和N-cadherin呈负相关,JMJD3可能通过调节乳腺癌细胞上皮间质转化,调控乳腺癌侵袭转移,其具体机制有待后续深入研究。

  • 图  1   干扰LSD1表达后Foxo3a蛋白水平变化

    Figure  1   Knockdown of LSD1 upregulated Foxo3a protein levels

    图  2   Transwell实验检测四组卵巢癌细胞的迁移情况(×200)

    Figure  2   Metastasis of ovarian cancer cells in four groups detected by Transwell assay (×200)

    图  3   Foxo3a介导LSD1对EMT相关蛋白表达的调控

    Figure  3   Foxo3a mediated the regulation of LSD1 on EMT-related protein expression

    表  1   四组卵巢癌细胞的生长抑制情况(x±s)

    Table  1   Proliferation of ovarian cancer cells in four groups(x±s)

    下载: 导出CSV

    表  2   四组卵巢癌细胞的迁移情况(x±s)

    Table  2   Metastasis of ovarian cancer cells in four groups (x±s)

    下载: 导出CSV
  • [1]

    Maldonado L, Hoque MO. Epigenomics and ovarian carcinoma[J]. Biomark Med, 2010, 4(4): 543-70. doi: 10.2217/bmm.10.72

    [2]

    Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin, 2010, 60(5): 277-300. doi: 10.3322/caac.20073

    [3]

    Cao C, Vasilatos SN, Bhargava R, et al. Functional interaction of histone deacetylase 5 (hdac5) and lysine-specific demethylase 1 (lsd1) promotes breast cancer progression[J]. Oncogene, 2017, 36(1): 133-45. doi: 10.1038/onc.2016.186

    [4]

    Amente S, Milazzo G, Sorrentino MC, et al. Lysine-specific demethylase (lsd1/kdm1a) and mycn cooperatively repress tumor suppressor genes in neuroblastoma J]. Oncotarget, 2015, 6(16): 14572-83. http://pubmedcentralcanada.ca/pmcc/articles/PMC4546488/

    [5]

    Sakamoto A, Hino S, Nagaoka K, et al. Lysine demethylase lsd1 coordinates glycolytic and mitochondrial metabolism in hepatocellular carcinoma cells[J]. Cancer Res, 2015, 75(7): 1445-56. doi: 10.1158/0008-5472.CAN-14-1560

    [6]

    Zhang X, Zhang X, Yu B, et al. Oncogene lsd1 is epigenetically suppressed by mir-137 overexpression in human non-small cell lung cancer [J]. Biochimie, 2017, 137: 12-9. doi: 10.1016/j.biochi.2017.02.010

    [7]

    Kauffman EC, Robinson BD, Downes MJ, et al. Role of androgen receptor and associated lysine-demethylase coregulators, lsd1 and jmjd2a, in localized and advanced human bladder cancer[J]. Mol Carcinog, 2011, 50(12): 931-44. doi: 10.1002/mc.20758

    [8]

    Mould DP, McGonagle AE, Wiseman DH, et al. Reversible inhibitors of lsd1 as therapeutic agents in acute myeloid leukemia: Clinical significance and progress to date[J]. Med Res Rev, 2015, 35(3): 586-618. doi: 10.1002/med.2015.35.issue-3

    [9]

    Konovalov S, Garcia-bassets I. Analysis of the levels of lysine-specific demethylase 1 (lsd1) mrna in human ovarian tumors and the effects of chemical lsd1 inhibitors in ovarian cancer cell lines [J]. J Ovarian Res, 2013, 6(1): 75. doi: 10.1186/1757-2215-6-75

    [10] 刘秀文, 魏野, 李袁霞, 等.沉默LSD1基因的表达可抑制卵巢癌H0890细胞的增殖并诱导其凋亡[J].肿瘤, 2016, 36(5): 485-95. http://kns.cnki.net/KCMS/detail/detail.aspx?filename=zzll201605001&dbname=CJFD&dbcode=CJFQ

    Liu XW, Wei Y, Li YX, et al. LSD1 gene-silencing inhibits proliferation and promotes apoptosis of ovarian cancer H08910 cells[J]. Zhong Liu, 2016, 36(5): 485-95. http://kns.cnki.net/KCMS/detail/detail.aspx?filename=zzll201605001&dbname=CJFD&dbcode=CJFQ

    [11]

    Lin H, Dai T, Xiong H, et al. Unregulated mir-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor foxo3a[J]. PLoS One, 2010, 5(12): e15797. http://www.ncbi.nlm.nih.gov/pubmed/21203424/

    [12]

    Mandinova A, Lefort K, Tommasi di Vignano A, et al. The FoxO3a gene is a key negative target of canonical notch signalling in the keratinocyte UVB response[J]. EMBO J, 2008, 27(8): 1243-54. doi: 10.1038/emboj.2008.45

    [13]

    Schulte JH, Lim S, Schramm A, et al. Lysine-specific demethy lase1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy[J]. Cancer Res, 2009, 65(5): 2065-71. http://cn.bing.com/academic/profile?id=f14e5d066d7cfffd2a36247f95dd323b&encoded=0&v=paper_preview&mkt=zh-cn

    [14]

    Huang Y, Nayak S, Jankowitz R, et al. Epigenetics in breast cancer: What's new?[J]. Breast Cancer Res, 2011, 13(6): 225. doi: 10.1186/bcr2925

    [15]

    Lv T, Yuan D, Miao X, et al. Over-expression of lsd1 promotes proliferation, migration and invasion in non-small cell lung cancer [J]. PLoS One, 2012, 7(4): e35065. doi: 10.1371/journal.pone.0035065

    [16]

    Katoh M, Igarashi M, Fukuda H, et al. Cancer genetics and genomics of human fox family genes[J]. Cancer Lett, 2013, 328(2): 198-206. doi: 10.1016/j.canlet.2012.09.017

    [17]

    Boix L, López-Oliva JM, Rhodes AC, et al. Restoring mir122 in human stem-like hepatocarcinoma cells, prompts tumor dormancy through smad-independent tgf-β pathway[J]. Oncotarget, 2016, 7(44): 71309-29. http://pubmedcentralcanada.ca/pmcc/articles/PMC5342080/?report=reader

    [18]

    Cheng CW, Chen PM, Hsien YH, et al. Foxo3a-mediated overexpression of microrna-622 suppresses tumor metastasis by repressing hypoxia-inducible factor-1α in erk-responsive lung cancer[J]. Oncotarget, 2015, 6(42): 44222-38. http://www.ncbi.nlm.nih.gov/pubmed/26528854

    [19]

    Yang XB, Zhao JJ, Huang CY, et al. Decreased expression of the foxo3a gene is associated with poor prognosis in primary gastric adenocarcinoma patients[J]. PLoS One, 2013, 8(10): e78158. doi: 10.1371/journal.pone.0078158

    [20]

    Das TP, Suman S, Alatassi H, et al. Inhibition of akt promotes foxo3a-dependent apoptosis in prostate cancer[J]. Cell Death Dis, 2016, 7: e2111. doi: 10.1038/cddis.2015.403

    [21]

    Kocak C, Kocak FE, Bayhan Z, et al. Value of immunohistochemical detection of foxo3a as a prognostic marker in human breast carcinoma[J]. Inter J Clin Expe Pathol, 2016, 9(10): 9938-50. http://www.researchgate.net/publication/309618777_Value_of_immunohistochemical_detection_of_FOXO3a_as_a_prognostic_marker_in_human_breast_carcinoma

    [22]

    Obradorhevia A, Serra-sitjar M, Rodríguez J, et al. The tumour suppressor foxo3 is a key regulator of mantle cell lymphoma proliferation and survival[J]. Br J Haematol, 2012, 156(3): 334-45. doi: 10.1111/bjh.2012.156.issue-3

    [23]

    Jiang Y, Zou L, Lu WQ, et al. Foxo3a expression is a prognostic marker in breast cancer[J]. PLoS One, 2013, 8(8): e70746. doi: 10.1371/journal.pone.0070746

    [24]

    Miller BH, Wahlestedt C. MicroRNA dysregulation in psychiatric disease[J]. Brain Res, 2010, 1338: 89-99. doi: 10.1016/j.brainres.2010.03.035

    [25]

    Feng S, Jin Y, Cui M, et al. Lysine-specific demethylase 1 (lsd1) inhibitor s2101 induces autophagy via the akt/mtor pathway in skov3 ovarian cancer cells[J]. Med Sci Monit, 2016, 22: 4742-8. doi: 10.12659/MSM.898825

    [26]

    Marlow LA, von Roemeling CA, Cooper SJ, et al. Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin a1: A paradigm shift that impacts current therapeutic strategies[J]. J Cell Sci, 2012, 125(18): 4253-63. doi: 10.1242/jcs.097428

  • 期刊类型引用(2)

    1. 苗晓红,袁志英,李媛,韩秀青,李光. 宫颈癌组织含Jumonji结构域的蛋白2B、造血相关PBX相互作用蛋白的表达与预后关系的分析. 中国性科学. 2023(01): 60-65 . 百度学术
    2. 徐小艳,王建君,闫琛,李川,刘微,杨金花. ALKBH5促进乳腺浸润性导管癌细胞上皮间质转化和血管生成并增强其侵袭和转移. 细胞与分子免疫学杂志. 2021(04): 355-361 . 百度学术

    其他类型引用(0)

图(3)  /  表(2)
计量
  • 文章访问数:  1224
  • HTML全文浏览量:  411
  • PDF下载量:  356
  • 被引次数: 2
出版历程
  • 收稿日期:  2017-12-04
  • 修回日期:  2018-02-21
  • 网络出版日期:  2024-01-12
  • 刊出日期:  2018-08-24

目录

/

返回文章
返回
x 关闭 永久关闭